skip to Main Content

Survival of Patients with Borderline Resectable Pancreatic Cancer who Received Neoadjuvant Therapy and Surgery

Newsfeed image, light gray text on dark gray background
It is difficult to successfully deliver multimodality therapy to patients with operable pancreatic cancer.

Data on the natural history of such efforts are necessary for physicians to guide shared decision-making with patients and families. We report the survival of consecutive patients with borderline resectable pancreatic cancer who received neoadjuvant therapy before surgery. Read more . . . 

Back To Top